Opinions

Novel evidence demonstrates the clinical utility of circulating tumour DNA in patients with HR+/HER2- cancers harbouring ESR1 and PIK3CA mutations 

Findings from recently presented studies support an upfront integration of ADCs in the treatment course, but some key questions are pending

Two studies investigating efficacy of bispecific T-cell engager tarlatamab and lurbinectedin–atezolizumab combination met their primary endpoints of survival

Recent studies have refined current knowledge on how to better treat this patient population, taking care of their unique needs and expectations

Defining patients most likely to respond, a better understanding of the host–tumour immune axis and clinical trials for specific subtypes are key to extending success

Adjuvant immunotherapy is still actual despite heterogeneity on its accessibility in Europe and fast advances in neoadjuvant immunotherapy

While strategies for drug de-escalation continue to be actively pursued, some challenges including insufficient funding of research still limit their applicability 

While the field is rapidly evolving, regulatory shifts and greater access to tumour profiling are now needed to realise the full benefits for patients

Final survival data from the TALAPRO-2 study support the use of a PARP inhibitor plus an androgen receptor pathway inhibitor 

Recent findings consolidate the role of liquid biopsy in the field, but prospective research is needed